Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 2/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.44 |
| ▸ | PRKACA | P17612 | 2/20 | 0.44 |
| ▸ | CDK2 | P24941 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.44 |
| ▸ | CDC7 | O00311 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | PAK4 | O96013 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL510677 | 0.87 | MPO (0.45) | TDP1ALDH1A1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL1106887 | 0.87 | ALDH1A1 (0.45) | TDP1ALDH1A1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL510471 | 0.87 | RAB9A (0.53) | TDP1ALDH1A1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL509559 | 0.83 | ALDH1A1 (0.41) | TDP1ALDH1A1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL511112 | 0.82 | MEN1 (0.46) | TDP1ALDH1A1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL15196482 | 0.80 | TDP1 (0.52) | TDP1ALDH1A1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL30025289 | 0.80 | RAB9A (0.41) | TDP1ALDH1A1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL509851 | 0.80 | RAB9A (0.41) | TDP1ALDH1A1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL510647 | 0.79 | KDM4E (0.43) | TDP1ALDH1A1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL30026398 | 0.78 | RAB9A (0.47) | TDP1ALDH1A1RAB9ASMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841327-B2 | Heterocycles substituted pyridine derivatives and antifungal agent containing thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-09-23 | — | — | US | disclosed |
| US-8841327-B2 | Heterocycles substituted pyridine derivatives and antifungal agent containing thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-09-23 | — | — | US | disclosed |
| US-8841327-B2 | Heterocycles substituted pyridine derivatives and antifungal agent containing thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-09-23 | — | — | US | disclosed |
| EP-1944303-B1 | PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROCYCLE AND FUNGICIDE CONTAINING THE SAME | EISAI R&D MAN CO LTD (JP) | 2013-08-21 | — | — | EP | disclosed |
| US-8507530-B2 | Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-13 | — | — | US | disclosed |
| US-8507530-B2 | Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-13 | — | — | US | disclosed |
| US-8507530-B2 | Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-13 | — | — | US | disclosed |
| US-8158657-B2 | Heterocycles substituted pyridine derivatives and antifungal agent containing thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-17 | — | — | US | disclosed |
| US-8158657-B2 | Heterocycles substituted pyridine derivatives and antifungal agent containing thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-17 | — | — | US | disclosed |
| US-8158657-B2 | Heterocycles substituted pyridine derivatives and antifungal agent containing thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-17 | — | — | US | disclosed |
| US-7691882-B2 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-06 | — | — | US | disclosed |
| US-7691882-B2 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-06 | — | — | US | disclosed |
| EP-2141171-A1 | PYRIDINE DERIVATIVE SUBSTITUTED WITH HETEROCYCLE AND PHOSPHONOAMINO AND ANTIFUNGAL AGENT CONTAINING THE SAME | Eisai R&D Management Co., Ltd. (JP) | 2010-01-06 | — | — | EP | disclosed |
| US-20090082403-A1 | PYRIDINE DERIVATIVES SUBSTITUTED BY HETEROCYCLIC RING AND PHOSPHONOAMINO GROUP, AND ANTI-FUNGAL AGENT CONTAINING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090082403-A1 | PYRIDINE DERIVATIVES SUBSTITUTED BY HETEROCYCLIC RING AND PHOSPHONOAMINO GROUP, AND ANTI-FUNGAL AGENT CONTAINING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090082403-A1 | PYRIDINE DERIVATIVES SUBSTITUTED BY HETEROCYCLIC RING AND PHOSPHONOAMINO GROUP, AND ANTI-FUNGAL AGENT CONTAINING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| EP-1944303-A1 | PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROCYCLE AND FUNGICIDE CONTAINING THE SAME | Eisai R&D Management Co., Ltd. (JP) | 2008-07-16 | — | — | EP | disclosed |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082403-A1 | PYRIDINE DERIVATIVES SUBSTITUTED BY HETEROCYCLIC RING AND PHOSPHONOAMINO GROUP, AND ANTI-FUNGAL AGENT CONTAINING SAME | ERG28, H1-2, H1-3 | TDP1 3169/4885ALDH1A1 3642/4885RAB9A 2523/4885 |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | GPI, ERG28, MAN2A1 | TDP1 4848/4885ALDH1A1 3327/4885RAB9A 3912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.